RecruitingPhase 1NCT06552416
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Marker Therapeutics, Inc.
- Intervention
- MT-401-OTS(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2025 – 2029
Study locations (3)
- City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- KU Cancer Center, Kansas City, Kansas, United States
Collaborators
University of Kansas Medical Center · H. Lee Moffitt Cancer Center and Research Institute · City of Hope National Medical Center · FDA Office of Orphan Products Development
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06552416 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07384715First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)Genmab
- RECRUITINGPHASE1NCT06670222Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)Groupe Francophone des Myelodysplasies
- RECRUITINGNANCT07121140Home Blood TransfusionsThomas Jefferson University
- RECRUITINGNANCT05924074Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)University Hospital, Bordeaux
- RECRUITINGNCT06379945Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)Instituto de Investigación Biomédica de Salamanca
- RECRUITINGPHASE1, PHASE2NCT05181735Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESAGroupe Francophone des Myelodysplasies
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04798339Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT04243785A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeEdgewood Oncology Inc.